文献速递痛风与晶体性关节病

慢性焦磷酸钙晶体炎症性关节炎中超说明书传统治疗与生物制剂的留存率、安全性和疗效

Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

这项回顾性队列研究在七个欧洲中心回顾了129例持续性炎症性和/或复发性急性焦磷酸钙晶体关节炎患者的病历,共启动194种治疗。秋水仙碱是最常用的一线治疗,托珠单抗24个月留存率高于阿那白滞素,甲氨蝶呤与秋水仙碱差异无统计学意义,各治疗疗效结局无显著差异。

要点

  • 秋水仙碱是最常用的一线治疗,被认为在三分之一至半数病例中有效。
  • 托珠单抗24个月留存率40%高于阿那白滞素18.5%(P<0.05)。
  • 甲氨蝶呤与秋水仙碱24个月留存率差异无统计学意义(P=0.10)。

核心结论

  • 每日秋水仙碱是慢性焦磷酸钙晶体炎症性关节炎的一线治疗,被认为在三分之一至半数病例中有效。
  • 二线治疗包括甲氨蝶呤和托珠单抗,其留存率高于阿那白滞素。

研究设计与样本

  • 这是一项回顾性队列研究,在七个欧洲中心回顾了诊断为持续性炎症性和/或复发性急性焦磷酸钙晶体关节炎患者的病历。
  • 共129例患者启动了194种治疗,收集基线特征,并在第3、6、12和24个月访视时评估治疗反应和安全性。

主要发现

  • 秋水仙碱一线使用n=73/86,甲氨蝶呤一线使用n=14/36,阿那白滞素n=27,托珠单抗n=25为最常用治疗;长期糖皮质激素、羟氯喹、卡那奴单抗和沙利鲁单抗偶尔使用。
  • 24个月药物留存率托珠单抗40%高于阿那白滞素18.5%(P<0.05),秋水仙碱29.1%与甲氨蝶呤44.4%差异无统计学意义(P=0.10)。
  • 不良事件导致秋水仙碱停药14.1%(100%为腹泻)、甲氨蝶呤4.3%、阿那白滞素31.8%、托珠单抗20%;其他停药与应答不足或失访相关。
  • 整个随访期间各治疗间疗效结局无显著差异。

关键数值与推荐

  • 24个月药物留存率:托珠单抗40% vs 阿那白滞素18.5%(P<0.05)。
  • 24个月药物留存率:秋水仙碱29.1% vs 甲氨蝶呤44.4%(P=0.10,差异无统计学意义)。
  • 不良事件导致停药比例:秋水仙碱14.1%(腹泻占100%)、甲氨蝶呤4.3%、阿那白滞素31.8%、托珠单抗20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Very little is known on the efficacy and safety of drugs for the management of chronic calcium pyrophosphate (CPP) crystal inflammatory arthritis. The objectives of this work were to describe the drugs used in the management of chronic CPP crystal inflammatory arthritis in expert European centres, and to examine treatment retention. METHODS: This was a retrospective cohort study. Charts from patients with a diagnosis of persistent inflammatory and/or recurrent acute CPP crystal arthritis were reviewed in seven European centres. Baseline characteristics were collected, and visits at months 3, 6, 12 and 24 included an assessment of treatment response and safety. RESULTS: One hundred and ninety-four treatments were initiated in 129 patients. Colchicine (used first-line in n = 73/86), methotrexate (used first-line in n = 14/36), anakinra (n = 27) and tocilizumab (n = 25) were the most prescribed treatments, while long-term corticosteroids, hydroxychloroquine, canakinumab and sarilumab were used occasionally. The 24-month on-drug retention was higher for tocilizumab (40%) than anakinra (18.5%) (P < 0.05), while the difference between colchicine (29.1%) and methotrexate (44.4%) was not statistically significant (P = 0.10). Adverse events led to 14.1% of colchicine discontinuations (100% of diarrhoea), 4.3% for methotrexate, 31.8% for anakinra and 20% for tocilizumab; all other discontinuations were related to insufficient response or losses to follow-up. Efficacy outcomes did not differ significantly between treatments throughout follow-up. CONCLUSION: Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Damart J, Filippou G, Andrès M, et al. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis. Rheumatology (Oxford). 2024. PMID: 37216917. doi:10.1093/rheumatology/kead228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。